Hypertension

Panelists discuss how poor medication adherence and comorbidities such as chronic kidney disease (CKD) contribute to uncontrolled hypertension despite the availability of numerous treatment options, highlighting key challenges in achieving effective blood pressure management.

Viet Le, PA-C, DMSc, breaks down new data and updates from AHA 24, spotlighting 3 specific trials and the applicability of artificial intelligence in care.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

In this episode, John Giacona, PhD, PA-C, shares insights from the 2024 AHA Hypertension Scientific Sessions, focusing on primary aldosteronism and renal denervation.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

The STOP-or-NOT trial found similar outcomes for continuation or discontinuation of RAS inhibitors before noncardiac surgery, supporting individualized decision-making.

On August 19, 2024, Liquidia Corporation announced the FDA's tentative approval of treprostinil inhalation powder for adults with PAH and PH-ILD.

A recent study found that noise exposure of power looms (≥ 85 decibels) puts workers at risk of their overall blood pressure increasing.

A study cautions the AHA's new PREVENT equations may underprescribe statins and antihypertensives, potentially causing 107,000 more ASCVD events in 10 years.

Individuals with both psoriasis and hypertension have approximately a 2-fold increased mortality risk, which is greater than the mortality risk for psoriasis or hypertension alone.

At Heart in Diabetes, full results of the GRACE trial detailed the benefits of relacorilant use from both parts of the 2-part, phase 3 trial.

Relacorilant achieves primary endpoint in phase 3 GRACE trial among patients with hypercortisolism and hyperglycemia, hypertension or both, with sNDA expected in Q3 2024.

Swapnil Hiremath, MD, MPH, explains the importance of 24-hour ambulatory blood pressure monitoring (ABPM) to rule out the possibility of white coat hypertension.

Matthew Nudy, MD, discusses a trio of meta-analyses examining the effects of intensive blood pressure control on various targets.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

Idorsia Ltd. announced the FDA's approval of aprocitentan (Tryvio) for treatment-resistant hypertension on March 20, 2024.

Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.

In new topline results from the KARDIA-2 trial, zilebesiran added to standard-of-care antihypertensive treatments showed significant reductions in systolic blood pressure.

Older adults who use a salt substitute had a 40% lower incidence of experiencing hypertension than people who use regular salt.

A recent survey indicates many US adults are unaware of their vital health metrics, highlighting the need for increased education on heart disease prevention.

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

On January 25, 2024, the day following the proposed PDUFA goal date, Liquidia Corporation announced the FDA was still reviewing the NDA for pulmonary hypertension with interstitial lung disease for treprostinil inhalation powder (Yutrepia).

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

The FDA has approved the second renal denervation device in the agency's history with the approval of Medtronic's Symplicity Spyral system.

Lowering blood pressure significantly reduced the risk of developing dementia among adults with hypertension in China compared to usual care.